Use of a GLP-1R Agonist to Treat Opioid Use Disorder

Inclusion Criteria: * Age 18 to 75 years * Diagnosed with an OUD seeking treatment at Caron Treatment Centers (CaronTC) and planning on being enrolled in a residential treatment plan for a minimum of 4 weeks * Women of childbearing potential must consent to use a medically accepted method of birth control or to abstain from sexual intercourse while in the study * Able and willing to provide informed consent prior to any study-related activities * Must be able to read and communicate in English sufficiently to complete all study requirements, including Ecology Momentary Assessment (EMA) Exclusion Criteria: * Age \< 18 or \> 75 years * Women who are pregnant, planning pregnancy, breastfeeding, or unwilling to use adequate contraceptive measures * History of angioedema, serious hypersensitivity reaction, or anaphylactic reaction to liraglutide or another glucagon-like peptide-1 receptor (GLP1R) agonist * Personal or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome type 2 (MEN 2) or thyroid nodule * Type I diabetes or history of diabetic ketoacidosis * Type II diabetes mellitus * Hypoglycemia on intake visit (blood glucose \< 70 mg/dL) * End-stage renal failure on dialysis or glomerular filtration rate (GFR) \<30 mL/min per 1.73 square meters or previous renal transplant * Severe hepatic impairment (AST or ALT levels \> 3 times upper limit of normal range) or previous liver transplant * Current or past diagnosis of panc…